MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-11-2026
Stryker Corporation Net Debt 2011-2026 | SYK
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Stryker Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 11 B | 8.68 B | 8.07 B | 10.1 B | 9.64 B | 10.3 B | 6.75 B | 6.24 B | 4.68 B | 3.6 B | 643 M | 2.18 B | 1.42 B | 367 M | 863 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 11 B | 367 M | 5.64 B |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Medical devices industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AxoGen
AXGN
|
15.2 M | $ 32.67 | 5.42 % | $ 1.5 B |  USA |
 |
Conformis
CFMS
|
-26.2 M | - | - | $ 16.4 M | USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
38.7 M | - | - | $ 1.77 B | USA |
 |
Acutus Medical
AFIB
|
14.2 M | - | -26.83 % | $ 2.62 M | USA |
 |
AdaptHealth Corp.
AHCO
|
1.64 B | $ 12.24 | 2.47 % | $ 1.65 B | USA |
 |
Cardiovascular Systems
CSII
|
-64.6 M | - | 0.15 % | $ 844 M | USA |
 |
Allied Healthcare Products
AHPI
|
-3.31 M | - | 3.58 % | $ 2.21 M | USA |
 |
ClearPoint Neuro
CLPT
|
3.85 M | $ 9.36 | 3.2 % | $ 265 M | USA |
 |
Dynatronics Corporation
DYNT
|
1.8 M | - | 14.99 % | $ 929 K | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
6.46 M | - | -5.86 % | $ 30.6 M | USA |
 |
Bruker Corporation
BRKR
|
1.91 B | $ 38.24 | 4.28 % | $ 5.7 K | USA |
 |
Second Sight Medical Products
EYES
|
2.62 M | - | -0.97 % | $ 54.4 M | USA |
 |
GBS
GBS
|
-4.38 M | - | -0.57 % | $ 7.12 M | USA |
 |
Apollo Endosurgery
APEN
|
-22.5 M | - | - | $ 475 M | USA |
 |
FONAR Corporation
FONR
|
-42.8 M | $ 18.61 | 0.13 % | $ 122 M | USA |
 |
Electromed
ELMD
|
-10.5 M | $ 24.41 | 2.89 % | $ 206 M | USA |
 |
Globus Medical
GMED
|
-511 M | $ 91.72 | 1.91 % | $ 12.4 B | USA |
 |
EDAP TMS S.A.
EDAP
|
-22.8 M | $ 3.34 | -1.82 % | $ 125 M |  France |
 |
CryoLife, Inc.
CRY
|
230 M | - | -4.14 % | $ 702 M | USA |
 |
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | USA |
 |
Helius Medical Technologies
HSDT
|
-5.12 M | $ 1.89 | 3.28 % | $ 1.15 M | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
529 M | $ 9.62 | 3.11 % | $ 741 M | USA |
 |
Align Technology
ALGN
|
-925 M | $ 178.59 | 7.02 % | $ 13.4 B | USA |
 |
Invacare Corporation
IVC
|
299 M | - | - | $ 24.7 M | USA |
 |
Axonics Modulation Technologies
AXNX
|
-230 M | - | - | $ 3.31 B | USA |
 |
Integer Holdings Corporation
ITGR
|
1.18 B | $ 87.43 | 2.73 % | $ 3.04 B | USA |
 |
Aziyo Biologics
AZYO
|
-32.4 M | - | 1.37 % | $ 20.5 M | USA |
 |
OrthoPediatrics Corp.
KIDS
|
83.3 M | $ 16.18 | 2.63 % | $ 380 M | USA |
 |
Soliton, Inc.
SOLY
|
-31.6 M | - | -1.42 % | $ 435 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
-9.02 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
-2.3 M | - | 0.03 % | $ 1.58 B |  Israel |
 |
LivaNova PLC
LIVN
|
-282 M | $ 64.67 | 1.78 % | $ 3.53 B |  Britain |
 |
Misonix, Inc.
MSON
|
5.72 M | - | - | $ 462 M | USA |
 |
LENSAR
LNSR
|
-10.2 M | $ 5.67 | 0.71 % | $ 67.8 M | USA |
 |
Neovasc
NVCN
|
-4.95 M | - | - | $ 111 M |  Canada |
 |
Medtronic PLC
MDT
|
23.6 B | $ 88.04 | 1.87 % | $ 113 B | USA |
 |
Butterfly Network
BFLY
|
-65.9 M | $ 4.18 | 3.21 % | $ 885 M | USA |
 |
Myomo
MYO
|
-4.79 M | $ 0.68 | -0.3 % | $ 28.5 M | USA |
 |
Intersect ENT, Inc.
XENT
|
50.8 M | - | - | $ 955 M | USA |
 |
Nevro Corp.
NVRO
|
93.4 M | - | - | $ 217 M | USA |
 |
Cytosorbents Corporation
CTSO
|
11 M | $ 0.64 | 4.94 % | $ 39.8 M | USA |
 |
BIOLASE
BIOL
|
6.1 M | - | -13.19 % | $ 166 K | USA |
 |
Delcath Systems
DCTH
|
-42.5 M | $ 9.84 | 1.76 % | $ 352 M | USA |
 |
BioSig Technologies
BSGM
|
252 K | - | 37.08 % | $ 85.7 M | USA |
 |
Boston Scientific Corporation
BSX
|
9.26 B | $ 62.3 | 0.71 % | $ 92.2 B | USA |
 |
Alphatec Holdings
ATEC
|
347 M | $ 11.45 | 3.76 % | $ 1.72 B | USA |
 |
IRIDEX Corporation
IRIX
|
-5.23 M | $ 1.14 | 10.68 % | $ 19.3 M | USA |
 |
CONMED Corporation
CNMD
|
802 M | $ 36.46 | 5.56 % | $ 1.13 B | USA |